Literature DB >> 11170944

Clinical outcomes of Estonian patients with primary multidrug-resistant versus drug-susceptible tuberculosis.

S Lockman1, A Kruuner, N Binkin, K Levina, Y Wang, M Danilovitsh, S Hoffner, J Tappero.   

Abstract

Little is known about the clinical outcomes of patients with primary multidrug-resistant (MDR) tuberculosis. Clinical outcomes among 46 patients in Estonia with primary MDR tuberculosis and 46 patients with pansusceptible tuberculosis were compared. Patients with MDR tuberculosis were more likely than those with pansensitive tuberculosis to have treatment failure (odds ratio, 8.9; 95% confidence interval [CI], 3.0-26.3) after adjusting for medical problems and weeks of effective treatment, often with second-line drugs. Ten patients (22%) with MDR tuberculosis and 2 (4%) with susceptible tuberculosis died of tuberculosis (P=.03). MDR tuberculosis (hazard ratio [HR], 7.8; 95% CI, 1.6-37.4), number of medical problems (HR, 2.5; 95% CI, 1.5-4.4), and male sex (HR, 5.8; 95% CI, 1.1-29.6) were associated with death due to tuberculosis in multivariable analysis. Human immunodeficiency virus test results were negative for all 55 patients tested. These findings underscore the urgent need for increased attention to prevention and treatment of MDR tuberculosis globally.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170944     DOI: 10.1086/318489

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  15 in total

1.  High prevalence of multidrug-resistant tuberculosis in Georgia.

Authors:  Nino Mdivani; Ekaterina Zangaladze; Natalia Volkova; Ekaterina Kourbatova; Thea Jibuti; Natalia Shubladze; Tamar Kutateladze; George Khechinashvili; Carlos del Rio; Archil Salakaia; Henry M Blumberg
Journal:  Int J Infect Dis       Date:  2008-06-02       Impact factor: 3.623

Review 2.  Risk factors for multidrug resistant tuberculosis in Europe: a systematic review.

Authors:  A Faustini; A J Hall; C A Perucci
Journal:  Thorax       Date:  2005-10-27       Impact factor: 9.139

3.  Comparing early treatment outcomes of MDR-TB in decentralised and centralised settings in KwaZulu-Natal, South Africa.

Authors:  M Loveday; K Wallengren; A Voce; B Margot; T Reddy; I Master; J Brust; K Chaiyachati; N Padayatchi
Journal:  Int J Tuberc Lung Dis       Date:  2012-02       Impact factor: 2.373

4.  High Frequency of First-Line Anti-Tuberculosis Drug Resistance among Persons with Chronic Pulmonary Tuberculosis at a Teaching Hospital Chest Clinic.

Authors:  A Forson; S Kudzawu; A Kwara; T Flanigan
Journal:  Ghana Med J       Date:  2010-06

5.  Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes.

Authors:  Dennis Falzon; Neel Gandhi; Giovanni B Migliori; Giovanni Sotgiu; Helen S Cox; Timothy H Holtz; Maria-Graciela Hollm-Delgado; Salmaan Keshavjee; Kathryn DeRiemer; Rosella Centis; Lia D'Ambrosio; Christoph G Lange; Melissa Bauer; Dick Menzies
Journal:  Eur Respir J       Date:  2012-10-25       Impact factor: 16.671

6.  Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors.

Authors:  Kocfa Chung-Delgado; Sonia Guillen-Bravo; Alejandro Revilla-Montag; Antonio Bernabe-Ortiz
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

7.  Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis.

Authors:  Mayara L Bastos; Hamidah Hussain; Karin Weyer; Lourdes Garcia-Garcia; Vaira Leimane; Chi Chiu Leung; Masahiro Narita; Jose M Penã; Alfredo Ponce-de-Leon; Kwonjune J Seung; Karen Shean; José Sifuentes-Osornio; Martie Van der Walt; Tjip S Van der Werf; Wing Wai Yew; Dick Menzies
Journal:  Clin Infect Dis       Date:  2014-08-05       Impact factor: 9.079

Review 8.  Tuberculosis treatment outcome monitoring in European Union countries: systematic review.

Authors:  Rob van Hest; Csaba Ködmön; Suzanne Verver; Connie G M Erkens; Masja Straetemans; Davide Manissero; Gerard de Vries
Journal:  Eur Respir J       Date:  2012-07-12       Impact factor: 16.671

9.  Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients.

Authors:  Shama D Ahuja; David Ashkin; Monika Avendano; Rita Banerjee; Melissa Bauer; Jamie N Bayona; Mercedes C Becerra; Andrea Benedetti; Marcos Burgos; Rosella Centis; Eward D Chan; Chen-Yuan Chiang; Helen Cox; Lia D'Ambrosio; Kathy DeRiemer; Nguyen Huy Dung; Donald Enarson; Dennis Falzon; Katherine Flanagan; Jennifer Flood; Maria L Garcia-Garcia; Neel Gandhi; Reuben M Granich; Maria G Hollm-Delgado; Timothy H Holtz; Michael D Iseman; Leah G Jarlsberg; Salmaan Keshavjee; Hye-Ryoun Kim; Won-Jung Koh; Joey Lancaster; Christophe Lange; Wiel C M de Lange; Vaira Leimane; Chi Chiu Leung; Jiehui Li; Dick Menzies; Giovanni B Migliori; Sergey P Mishustin; Carole D Mitnick; Masa Narita; Philly O'Riordan; Madhukar Pai; Domingo Palmero; Seung-kyu Park; Geoffrey Pasvol; Jose Peña; Carlos Pérez-Guzmán; Maria I D Quelapio; Alfredo Ponce-de-Leon; Vija Riekstina; Jerome Robert; Sarah Royce; H Simon Schaaf; Kwonjune J Seung; Lena Shah; Tae Sun Shim; Sonya S Shin; Yuji Shiraishi; José Sifuentes-Osornio; Giovanni Sotgiu; Matthew J Strand; Payam Tabarsi; Thelma E Tupasi; Robert van Altena; Martie Van der Walt; Tjip S Van der Werf; Mario H Vargas; Pirett Viiklepp; Janice Westenhouse; Wing Wai Yew; Jae-Joon Yim
Journal:  PLoS Med       Date:  2012-08-28       Impact factor: 11.069

10.  Multidrug-resistant tuberculosis in central Asia.

Authors:  Helen Suzanne Cox; Juan Daniel Orozco; Roy Male; Sabine Ruesch-Gerdes; Dennis Falzon; Ian Small; Darebay Doshetov; Yared Kebede; Mohammed Aziz
Journal:  Emerg Infect Dis       Date:  2004-05       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.